Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adaptive Biotechnologies Corp
(NQ:
ADPT
)
4.860
+0.460 (+10.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adaptive Biotechnologies Corp
< Previous
1
2
Next >
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
July 11, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
May 31, 2024
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
May 07, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
April 17, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
April 02, 2024
Announces CFO transition
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
March 27, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
February 22, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
January 29, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
December 09, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
December 05, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 07, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
November 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Announces Launch of Epic Integration for clonoSEQ®
September 13, 2023
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
July 10, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
June 02, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
May 24, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 12, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
May 09, 2023
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
May 03, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
April 25, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
April 12, 2023
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
April 06, 2023
From
Adaptive Biotechnologies
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.